ViiV healthcare
Apr 28, 2020
In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up
Merck has collaborated with the Seattle-based Institute for Systems Biology (ISB) to further study novel coronavirus SARS-CoV-2. The primary goal of the collaboration will be to investigate the molecular pathway of SARS-CoV-2 and aetiology of COVID-19 with the intent of finding an effective and standard treatm...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
